Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
ACRES Commercial Realty Investor Alert: Kahn Swick & Foti, LLC Investigates ACRES Commercial Realty Corp. - ACR
ACR Stock Alert: Halper Sadeh LLC is Investigating Whether ACRES Commercial Realty Corp. is Obtaining a Fair Price for its Shareholders
REITs Excel, Earnings Swell, Fed Rebels
ACRES Commercial Realty Corp. (ACR) Q1 2026 Earnings Call Transcript
ACR.PR.D: A Large Yield From This REIT Preferred Equity
ACRES Commercial (ACR) Q1 Earnings Meet Estimates
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FIRST QUARTER 2026
ACRES Commercial Realty Corp. Announces Agreement to Internalize Management and Acquire ACRES Capital Corp.
Acres Commercial Realty: The High-Yielding Preferred Stock Could Be Interesting
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
ACRES Commercial Realty Corp. to Report Results for First Quarter 2026
Reviewing ACRES Commercial Realty (NYSE:ACR) and Two Harbors Investments (NYSE:TWO)
ACRES Commercial Realty: Discount To Remain Sticky Given Inflation Expectations
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
AGNC Investment (NASDAQ:AGNCZ) versus ACRES Commercial Realty (NYSE:ACR) Financial Review
ACRES Commercial Realty Corp. (ACR) Q4 2025 Earnings Call Transcript
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2025 AND YEAR ENDED DECEMBER 31, 2025
ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock
ACRES Commercial Realty (NYSE:ACR) versus KKR Real Estate Finance Trust (NYSE:KREF) Head-To-Head Contrast
ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2025
ACRES Commercial Realty Corp. (NYSE:ACR) Given Consensus Rating of “Moderate Buy” by Analysts
Insider Selling: ACRES Commercial Realty (NYSE:ACR) Major Shareholder Sells $114,194.20 in Stock
ACRES Commercial Realty (NYSE:ACR) Major Shareholder Sells $15,272.44 in Stock
ACRES Commercial Realty Corp. Announces Pricing of a $1.0 Billion CLO Backed by Commercial Mortgage Loans
Eagle Point Credit Management Sells 5,400 Shares of ACRES Commercial Realty (NYSE:ACR) Stock
Eagle Point Credit Management Sells 13,979 Shares of ACRES Commercial Realty (NYSE:ACR) Stock
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
ACRES Commercial Realty (NYSE:ACR) Major Shareholder Eagle Point Credit Management Sells 5,000 Shares of Stock
ACRES Commercial Realty Corp. (NYSE:ACR) Given Average Recommendation of “Moderate Buy” by Analysts
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock
Contrasting Cherry Hill Mortgage Investment (NYSE:CHMI) & ACRES Commercial Realty (NYSE:ACR)
ACRES Commercial Realty: Book Value Expands As Buybacks Shrink Outstanding Shares
ACR Poker's Dual Venom PKO Tournaments Deliver Knockout Success, Smashing Guaranteed Prize Pools to Award $7.8 million to Players
ACRES Commercial Realty Corp. (ACR) Q3 2025 Earnings Call Transcript
ACRES Commercial Realty Corp. Reauthorizes an Additional $7.5 Million Share Repurchase Program
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2025
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors